

Michigan Pharmacy and Therapeutics Committee
Meeting of July 21, 2009
DRAFT DRAFT DRAFT Minutes DRAFT DRAFT DRAFT

Introductions: Committee members present: Drs. Inman, Arend, Thill, Dorfman, Bradley, Nedd, Perri, Fiechtner, Dake, Dillon
State staff present: Sue Moran, RN, Debera Eggleston, MD, George Baker, MD, Tom Welch, Heather Slawinski
First Health staff present: Annette Paul, RPh., Donna Johnson, RPh.

Presentation of CNS Workgroup Discussion: Dr. Bradley and Dr. Dillon summarized comments from the workgroup regarding monitoring of behavioral health drugs and such issues as poly pharmacy of atypical antipsychotics. Formal recommendations were not made because the Legislature has yet to act on necessary changes which would permit placing the behavioral health medications on the preferred drug list with prior authorization.

Public Comment: Dr. Nedd asked that comment be the next agenda item rather than at the end of the meeting so the Committee could hear input from interested individuals. The following persons commented:

- J. Plewes, MD Eli Lilly regarding Zyprexa
- C. Patel, PharmD, Eli Lilly regarding Cymbalta
- R. Berchou, PharmD, Detroit-Wayne County Community Mental Health (CMH) regarding the need and reasons for open access of these medications
- M. Reinstein, PhD, Mental Health Association of Michigan regarding the need for open access to these drugs
- A. Gorelick, MPH, Epilepsy Foundation of Michigan, regarding the consequences of limiting access to antiepileptics and overlap between occurrence of seizures and behavioral health conditions in patient with epilepsy
- L. Ackerman, NAMI, regarding personal history and need for open access to newer drugs
- A. Masterson, MD, Forest View Hospital, regarding use of these drugs in children
- K. Gail, CNP, Michigan Council of Nurse Practitioners, regarding current usage and need for open access to these drugs
- A. La, PharmD, AstraZeneca, regarding Seroquel and Seoquel XR
- L. Rosen, MD, Oakland County CMH regarding open access to these medications
- W. Guy, MD, Easter Seals and Oakland CMH regarding need for open access
- D. Tanski, MD, University of Michigan, regarding open access and clinical algorithms
- G. Stockton, PharmD, BMS, supporting open access to all behavioral health medications
- H. Huebl, MD regarding need for open access
- R. Vik, Azurpharma, regarding Fazaclo
- R. Hegeman-Dingle, Pfizer, regarding Geodon, Lyrica and supporting open access
- R. Atkins, MD, Forest, regarding need for open access
- K. Beroza, MD, Central Michigan CMH, regarding unique characteristics of patients with mental health conditions, and need for open access or more realistic measures to manage
- M. Scruggs, Grand Rapids, regarding open access

Committee Discussion: Committee members had asked several speakers above about their thoughts on poly pharmacy of antipsychotic medications and different strategies to deal with minimizing this practice. Dr. Dillon summarized thoughts regarding the issue. The Committee discussed briefly the principles of formulary management put forth by Community Mental Health Directors regarding antipsychotics, antidepressants, and anticonvulsants used for mental health conditions. Drs. Dillon and Bradley acknowledged two members of the audience who also briefly stated their views. The Committee proposed consideration of adding a class to the preferred drug list for fibromyalgia treatments, and this will be explored further. Finally, Dr. Bradley summarized the position that the Committee would await legislative action on this issue.

Next meeting is Tuesday, September 1, 2009